- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Focal Segmental Sclerosis Associated with the Novel Multi-tyrosine Kinase Inhibitor Ponatinib
-
- Arai Hiroyuki
- Department of Nephrology, Kyoto University Graduate School of Medicine, Japan
-
- Yamamoto Shinya
- Department of Nephrology, Kyoto University Graduate School of Medicine, Japan
-
- Matsubara Takeshi
- Department of Nephrology, Kyoto University Graduate School of Medicine, Japan
-
- Miyake Takafumi
- Department of Nephrology, Kyoto University Graduate School of Medicine, Japan
-
- Tochio Akira
- Department of Nephrology, Kyoto University Graduate School of Medicine, Japan Department of Nephrology, Japanese Red Cross Society Wakayama Medical Center, Japan
-
- Mii Akiko
- Department of Nephrology, Nippon Medical School, Japan
-
- Shimizu Akira
- Department of Analytic Human Pathology, Nippon Medical School, Japan
-
- Minamiguchi Sachiko
- Department of Diagnostic Pathology, Kyoto University Hospital, Japan
-
- Muso Eri
- Division of Nephrology and Dialysis, Kitano Hospital, Japan Department of Food and Nutrition, Faculty of Contemporary Home Economics, Kyoto Kacho University, Japan
-
- Yanagita Motoko
- Department of Nephrology, Kyoto University Graduate School of Medicine, Japan Institute for the Advanced Study of Human Biology (ASHBi), Kyoto University, Japan
Search this article
Description
<p>Ponatinib is a novel multi-tyrosine kinase inhibitor (TKI) with potent inhibitory activity against refractory chronic myeloid leukemia (CML). Despite its high clinical efficacy, ponatinib induces various adverse events due to its multi-target characteristic. However, renal complications associated with ponatinib are rare. A 76-year-old woman had a history of chronic myeloid leukemia (CML) resistant to imatinib and nilotinib. Our patient developed proteinuria and renal function deterioration during treatment with ponatinib but not with imatinib or nilotinib. We herein report the first case of a patient with secondary focal segmental glomerulosclerosis (FSGS) with partial glomerular collapse induced by ponatinib treatment. </p>
Journal
-
- Internal Medicine
-
Internal Medicine 62 (18), 2693-2698, 2023-09-15
The Japanese Society of Internal Medicine
